Telehealth for Initial Evaluation and Prescription of Low-Dose Topical Estrogen for Vaginal Atrophy

Assessment Considerations for Telehealth Evaluation

Vaginal atrophy symptoms, including vaginal dryness, itching, burning sensation, discomfort during intercourse, and vaginal discharge, can be effectively assessed via telehealth to determine the severity and impact of symptoms on quality of life and sexual function in patients 1
A thorough medication review is crucial during telehealth to identify potential contraindications, such as the use of aromatase inhibitors, which may influence treatment decisions for patients with vaginal atrophy 1, 2
History of hormone-dependent cancers should be thoroughly evaluated as this may influence treatment decisions for patients with vaginal atrophy, according to the National Comprehensive Cancer Network 3, 1

The American College of Obstetricians and Gynecologists recommends regular use of over-the-counter vaginal moisturizers for daily maintenance of vaginal tissue health in patients with vaginal atrophy 1, 2
Water-based or silicone-based lubricants are recommended for use during sexual activity to alleviate symptoms of vaginal atrophy 1, 2
Topical vitamin D or E may be considered for additional symptom relief in patients with vaginal atrophy 1, 2
Low-dose vaginal estrogen therapy, available in several forms, including vaginal estrogen tablets, creams, and rings, may be prescribed via telehealth when non-hormonal options fail, with consideration of the patient's medical history and potential risks 1
DHEA (prasterone) may be considered for vaginal dryness and pain with sexual activity in patients with vaginal atrophy, according to the National Comprehensive Cancer Network 3, 1

Women with a history of hormone-dependent cancers require special consideration, and non-hormonal options should be tried first, according to the National Comprehensive Cancer Network 3, 1
Estriol-containing preparations may be preferable for women on aromatase inhibitors as estriol is a weaker estrogen, reducing potential risks 1

Failing to recognize that vaginal estrogen absorption is variable, which raises concerns in patients with a history of breast cancer, is a potential pitfall in telehealth management 1
Not discussing risks and benefits thoroughly with patients, especially those with a history of breast cancer, is essential to avoid in telehealth management 1
Incomplete assessment of contraindications, such as undiagnosed abnormal vaginal bleeding, which would require in-person evaluation, is a critical pitfall to avoid in telehealth management 1, 4

Abnormal vaginal bleeding that has not been diagnosed requires in-person evaluation to rule out other causes of symptoms 1
Physical examination is necessary to rule out other causes of symptoms, such as pelvic masses or abnormalities, and to assess the severity of vaginal atrophy 1
History of hormone-dependent cancers requires more thorough evaluation, including in-person assessment, to determine the best course of treatment 3, 1
Symptoms not responding to initial telehealth-prescribed treatments require in-person evaluation to reassess the patient's condition and adjust the treatment plan accordingly 1, 2